The present disclosure provides binding proteins, including TCRs, that specifically bind human cyclin A1 (CCNA1), host cells expressing such antigen specific binding proteins, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress CCNA1, such as in cancer.